Records 1-10 (of 10 Records) |
Query Trace: Bell's Palsy[original query] |
---|
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Dayan Gustavo H, et al. The Lancet. Respiratory medicine 2023 0 0. |
Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis. Kim Hye Jun, et al. Diabetes & metabolism journal 2023 0 0. |
Bell's Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis A Rafati et al, MEDRXIV, October 26, 2022
Our meta-analysis suggests a higher incidence of BP among vaccinated vs. placebo groups. BP occurrence did not significantly differ between Pfizer/BioNTech and Oxford/AstraZeneca vaccines. SARS-CoV-2 infection posed a significantly greater risk for BP than SARS-CoV-2 vaccines.
|
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand? Aliasin Mohammad Mahdi, et al. Reviews in the neurosciences 2022 0 0. |
Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Li Xintong et al. BMJ (Clinical research ed.) 2022 3 e068373
8?330?497 people who received at least one dose of covid-19 vaccines ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, or Ad.26.COV2.S between the rollout of the vaccination campaigns and end of data availability (UK: 9 May 2021; Spain: 30 June 2021). The study sample also comprised a cohort of 735?870 unvaccinated individuals with a first positive reverse transcription polymerase chain reaction test result for SARS-CoV-2 from 1 September 2020, and 14?330?080 participants from the general population. No safety signal was observed between covid-19 vaccines and the immune mediated neurological events of Bell’s palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. An increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome was, however, observed for people with SARS-CoV-2 infection.
|
Artificial intelligence-enabled social media analysis for pharmacovigilance of COVID-19 vaccinations in the United Kingdom: Observational Study. Hussain Zain, et al. JMIR public health and surveillance 2022 0 0. |
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection M Patone et al, Nature Medicine, October 25, 2021
We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28?days after a first dose of ChAdOx1nCoV-19 (n?=?20,417,752) or BNT162b2 (n?=?12,134,782), and after a SARS-CoV-2-positive test (n?=?2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21?days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21?days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21?days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28?days).
|
Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data. Huh Kyungmin, et al. Journal of Korean medical science 2021 3 0. (9) e67 |
Bell's palsy in a pediatric patient with hyper IgM syndrome and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Theophanous Christos, et al. Brain & development 2020 0 0. (2) 357-359 |
Otolaryngological symptoms in COVID-19. Elibol Elif, et al. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020 0 0. (4) 1233-1236 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 18, 2024
- Content source: